134 related articles for article (PubMed ID: 38588613)
1. Overcoming statin resistance in prostate cancer cells by targeting the 3-hydroxy-3-methylglutaryl-CoA-reductase.
Göbel A; Pählig S; Motz A; Breining D; Traikov S; Hofbauer LC; Rachner TD
Biochem Biophys Res Commun; 2024 May; 710():149841. PubMed ID: 38588613
[TBL] [Abstract][Full Text] [Related]
2. Induction of 3-hydroxy-3-methylglutaryl-CoA reductase mediates statin resistance in breast cancer cells.
Göbel A; Breining D; Rauner M; Hofbauer LC; Rachner TD
Cell Death Dis; 2019 Jan; 10(2):91. PubMed ID: 30692522
[TBL] [Abstract][Full Text] [Related]
3. An actionable sterol-regulated feedback loop modulates statin sensitivity in prostate cancer.
Longo J; Mullen PJ; Yu R; van Leeuwen JE; Masoomian M; Woon DTS; Wang Y; Chen EX; Hamilton RJ; Sweet JM; van der Kwast TH; Fleshner NE; Penn LZ
Mol Metab; 2019 Jul; 25():119-130. PubMed ID: 31023626
[TBL] [Abstract][Full Text] [Related]
4. HMG-CoA reductase degrader, SR-12813, counteracts statin-induced upregulation of HMG-CoA reductase and augments the anticancer effect of atorvastatin.
Zhou Y; Tashiro J; Kamatani S; Irie N; Suzuki A; Ishikawa T; Warita K; Oltvai ZN; Warita T
Biochem Biophys Res Commun; 2023 Oct; 677():13-19. PubMed ID: 37541087
[TBL] [Abstract][Full Text] [Related]
5. Effect of simvastatin on castration-resistant prostate cancer cells.
Kim JH; Cox ME; Wasan KM
Lipids Health Dis; 2014 Mar; 13():56. PubMed ID: 24666612
[TBL] [Abstract][Full Text] [Related]
6. Differential efficacy of 3-hydroxy-3-methylglutaryl CoA reductase inhibitors on the cell cycle of prostate cancer cells.
Sivaprasad U; Abbas T; Dutta A
Mol Cancer Ther; 2006 Sep; 5(9):2310-6. PubMed ID: 16985065
[TBL] [Abstract][Full Text] [Related]
7. High doses of atorvastatin and simvastatin induce key enzymes involved in VLDL production.
Roglans N; Verd JC; Peris C; Alegret M; Vázquez M; Adzet T; Díaz C; Hernández G; Laguna JC; Sánchez RM
Lipids; 2002 May; 37(5):445-54. PubMed ID: 12056585
[TBL] [Abstract][Full Text] [Related]
8. Alternative splicing of 3-hydroxy-3-methylglutaryl coenzyme A reductase is associated with plasma low-density lipoprotein cholesterol response to simvastatin.
Medina MW; Gao F; Ruan W; Rotter JI; Krauss RM
Circulation; 2008 Jul; 118(4):355-62. PubMed ID: 18559695
[TBL] [Abstract][Full Text] [Related]
9. CYP11A1 silencing suppresses HMGCR expression via cholesterol accumulation and sensitizes CRPC cell line DU-145 to atorvastatin.
Tashiro J; Sugiura A; Warita T; Irie N; Dwi Cahyadi D; Ishikawa T; Warita K
J Pharmacol Sci; 2023 Nov; 153(3):104-112. PubMed ID: 37770151
[TBL] [Abstract][Full Text] [Related]
10. The effects of statins on the mevalonic acid pathway in recombinant yeast strains expressing human HMG-CoA reductase.
Maciejak A; Leszczynska A; Warchol I; Gora M; Kaminska J; Plochocka D; Wysocka-Kapcinska M; Tulacz D; Siedlecka J; Swiezewska E; Sojka M; Danikiewicz W; Odolczyk N; Szkopinska A; Sygitowicz G; Burzynska B
BMC Biotechnol; 2013 Aug; 13():68. PubMed ID: 24128347
[TBL] [Abstract][Full Text] [Related]
11. Inflammatory stress induces statin resistance by disrupting 3-hydroxy-3-methylglutaryl-CoA reductase feedback regulation.
Chen Y; Ku H; Zhao L; Wheeler DC; Li LC; Li Q; Varghese Z; Moorhead JF; Powis SH; Huang A; Ruan XZ
Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):365-76. PubMed ID: 24233489
[TBL] [Abstract][Full Text] [Related]
12. Endogenous sterol intermediates of the mevalonate pathway regulate HMGCR degradation and SREBP-2 processing.
Chen L; Ma MY; Sun M; Jiang LY; Zhao XT; Fang XX; Man Lam S; Shui GH; Luo J; Shi XJ; Song BL
J Lipid Res; 2019 Oct; 60(10):1765-1775. PubMed ID: 31455613
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-185 and 342 inhibit tumorigenicity and induce apoptosis through blockade of the SREBP metabolic pathway in prostate cancer cells.
Li X; Chen YT; Josson S; Mukhopadhyay NK; Kim J; Freeman MR; Huang WC
PLoS One; 2013; 8(8):e70987. PubMed ID: 23951060
[TBL] [Abstract][Full Text] [Related]
14. Differential effects of pravastatin and simvastatin on the growth of tumor cells from different organ sites.
Menter DG; Ramsauer VP; Harirforoosh S; Chakraborty K; Yang P; Hsi L; Newman RA; Krishnan K
PLoS One; 2011; 6(12):e28813. PubMed ID: 22216116
[TBL] [Abstract][Full Text] [Related]
15. Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial.
Bjarnadottir O; Romero Q; Bendahl PO; Jirström K; Rydén L; Loman N; Uhlén M; Johannesson H; Rose C; Grabau D; Borgquist S
Breast Cancer Res Treat; 2013 Apr; 138(2):499-508. PubMed ID: 23471651
[TBL] [Abstract][Full Text] [Related]
16. HNRNPA1 regulates HMGCR alternative splicing and modulates cellular cholesterol metabolism.
Yu CY; Theusch E; Lo K; Mangravite LM; Naidoo D; Kutilova M; Medina MW
Hum Mol Genet; 2014 Jan; 23(2):319-32. PubMed ID: 24001602
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of cholesterol biosynthesis overcomes enzalutamide resistance in castration-resistant prostate cancer (CRPC).
Kong Y; Cheng L; Mao F; Zhang Z; Zhang Y; Farah E; Bosler J; Bai Y; Ahmad N; Kuang S; Li L; Liu X
J Biol Chem; 2018 Sep; 293(37):14328-14341. PubMed ID: 30089652
[TBL] [Abstract][Full Text] [Related]
18. Resveratrol potentiates effect of simvastatin on inhibition of mevalonate pathway in human endometrial stromal cells.
Villanueva JA; Sokalska A; Cress AB; Ortega I; Bruner-Tran KL; Osteen KG; Duleba AJ
J Clin Endocrinol Metab; 2013 Mar; 98(3):E455-62. PubMed ID: 23386644
[TBL] [Abstract][Full Text] [Related]
19. Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease.
Yeganeh B; Wiechec E; Ande SR; Sharma P; Moghadam AR; Post M; Freed DH; Hashemi M; Shojaei S; Zeki AA; Ghavami S
Pharmacol Ther; 2014 Jul; 143(1):87-110. PubMed ID: 24582968
[TBL] [Abstract][Full Text] [Related]
20. Explication of interactions between HMGCR isoform 2 and various statins through In silico modeling and docking.
Karthik MV; Satya Deepak MV; Shukla P
Comput Biol Med; 2012 Feb; 42(2):156-63. PubMed ID: 22177940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
